Related Experiment Videos
Regulating pharmaceutical companies' financial largesse
Ronen Avraham1,2, Charles Silver3
1The Buchmann Faculty of Law, Tel Aviv University, Tel Aviv, Israel. Ronen3112@gmail.com.
Israel Journal of Health Policy Research
|May 16, 2018
Summary
Despite a 2010 law mandating transparency in pharmaceutical payments to physicians, its effectiveness is limited. Loopholes and lack of awareness hinder its impact on healthcare conflicts of interest.
Area of Science:
- Health Policy and Law
- Medical Ethics
- Pharmaceutical Industry Regulation
Background:
- A 2010 amendment to Israel's National Health Insurance Law mandates annual reporting of payments from pharmaceutical companies (PCs) to healthcare professionals and organizations.
- The law aimed to enhance transparency and regulate potential conflicts of interest arising from financial relationships between PCs and physicians.
- Previous research by Nissanholtz-Gannot and Yenkellevich (NGY) explored stakeholder perceptions of this amendment's impact.
Purpose of the Study:
- To critically review the findings of the NGY study on the impact of the 2010 Israeli law regarding pharmaceutical payments.
- To assess the actual increase in transparency for patients and evaluate the effectiveness of the implemented regulations.
- To propose alternative strategies for enhancing patient oversight and mitigating conflicts of interest.
Main Methods:
- Critical analysis of the NGY study, which utilized interviews with various stakeholders.
- Examination of government reporting data to assess transparency levels concerning individual physicians versus institutions.
- Literature review and policy analysis to evaluate regulatory effectiveness and propose patient-centric solutions.
Main Results:
- The 2010 amendment has not significantly increased transparency for patients, as reports often obscure individual physician financial ties.
- Awareness of the amendment is low, particularly among physicians, and perceived loopholes limit its practical effectiveness.
- Improvements in transparency culture appear driven more by international pressure on multinational PCs than by the Israeli legislation itself.
Conclusions:
- Skepticism regarding the efficacy of self-regulation and current government oversight mechanisms in addressing pharmaceutical industry influence.
- The current legal framework fails to provide adequate transparency to patients regarding financial relationships in healthcare.
- Recommendations include facilitating class actions for fiduciary duty enforcement and restructuring drug co-payments to highlight relative efficacy.